Aviso Financial Inc. Grows Stock Holdings in Sanofi $SNY

Aviso Financial Inc. boosted its holdings in shares of Sanofi (NASDAQ:SNY) by 4.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 45,035 shares of the company’s stock after purchasing an additional 1,838 shares during the period. Aviso Financial Inc.’s holdings in Sanofi were worth $2,176,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Ameritas Advisory Services LLC acquired a new position in shares of Sanofi in the second quarter worth about $28,000. Accent Capital Management LLC acquired a new stake in shares of Sanofi during the 1st quarter valued at about $29,000. Eastern Bank increased its stake in shares of Sanofi by 121.0% in the 1st quarter. Eastern Bank now owns 548 shares of the company’s stock valued at $30,000 after purchasing an additional 300 shares in the last quarter. Banque Transatlantique SA acquired a new position in Sanofi in the 1st quarter worth about $33,000. Finally, Brentview Investment Management LLC acquired a new position in Sanofi in the 1st quarter worth about $42,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Performance

Shares of SNY stock opened at $49.15 on Tuesday. Sanofi has a one year low of $44.62 and a one year high of $60.12. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.94 and a current ratio of 1.06. The firm’s 50 day moving average price is $49.34 and its 200-day moving average price is $49.24. The firm has a market cap of $120.69 billion, a P/E ratio of 11.51, a P/E/G ratio of 1.38 and a beta of 0.49.

Sanofi (NASDAQ:SNY) last released its earnings results on Friday, October 24th. The company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.10. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The company had revenue of $14.53 billion during the quarter, compared to the consensus estimate of $12.62 billion. During the same period in the previous year, the company posted $2.25 EPS. Sanofi’s revenue was down 7.5% compared to the same quarter last year. As a group, equities research analysts predict that Sanofi will post 4.36 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on SNY shares. Wall Street Zen upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Sanofi in a research note on Tuesday, November 11th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. JPMorgan Chase & Co. raised Sanofi from a “neutral” rating to an “overweight” rating in a report on Friday, August 8th. Finally, Morgan Stanley raised Sanofi from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $56.00 to $58.00 in a research note on Monday, September 8th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $62.67.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.